INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 128 filers reported holding INOVIO PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,135 | -97.6% | 13,200 | -97.2% | 0.00% | -100.0% |
| Q2 2023 | $212,891 | +1160.3% | 476,800 | +2214.6% | 0.00% | – |
| Q1 2023 | $16,892 | -99.2% | 20,600 | -98.4% | 0.00% | -100.0% |
| Q4 2022 | $2,045,472 | -47.6% | 1,311,200 | -42.0% | 0.01% | -45.5% |
| Q3 2022 | $3,901,000 | -25.6% | 2,261,400 | -25.4% | 0.01% | -26.7% |
| Q2 2022 | $5,243,000 | +759.5% | 3,030,700 | +1682.8% | 0.02% | +650.0% |
| Q1 2022 | $610,000 | +18.9% | 170,000 | +146.7% | 0.00% | 0.0% |
| Q1 2020 | $513,000 | +224.7% | 68,900 | +43.5% | 0.00% | – |
| Q4 2019 | $158,000 | +119.4% | 48,000 | +36.0% | 0.00% | – |
| Q3 2019 | $72,000 | +28.6% | 35,300 | +85.3% | 0.00% | – |
| Q2 2019 | $56,000 | -5.1% | 19,050 | +79.7% | 0.00% | – |
| Q3 2018 | $59,000 | – | 10,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |